⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DVA News
DaVita Inc.
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
globenewswire.com
DVA
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
globenewswire.com
DVA
CG
DaVita Celebrates 20 Years on Fortune's List of World's Most Admired Companies
accessnewswire.com
DVA
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
prnewswire.com
DVA
More Than 30 Million Americans Living with Rare Diseases
prnewswire.com
AMGN
SNY
AGIO
ASND
DVA
INCY
NVS
PFE
REGN
UCB
National Donor Day Spotlight: DaVita Patient Care Technician Donates Kidney
accessnewswire.com
DVA
Corporate Knights Emphasizes Speed in Sustainability Rankings
accessnewswire.com
FLNC
DVA
DaVita Inc. 4th Quarter 2025 Results
prnewswire.com
DVA
Elara Caring Secures New Strategic Investment from Ares and DaVita
businesswire.com
ARES
DVA
End-Stage Renal Disease Market Projected to Reach US$ 573.86 Billion by 2035, Supported by Expanding Treatment Infrastructure and Care Delivery Says Astute Analytica
globenewswire.com
DVA
FMS